- Home
- LEGH vs EYPT Comparison
LEGH vs EYPT Comparison
Compare LEGH & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- EYPT
- Stock Information
- Founded
- LEGH 2005
- EYPT 1987
- Country
- LEGH United States
- EYPT United States
- Employees
- LEGH N/A
- EYPT N/A
- Industry
- LEGH Homebuilding
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- LEGH Consumer Discretionary
- EYPT Industrials
- Exchange
- LEGH Nasdaq
- EYPT Nasdaq
- Market Cap
- LEGH 588.8M
- EYPT 579.4M
- IPO Year
- LEGH 2018
- EYPT 2005
- Fundamental
- Price
- LEGH $23.04
- EYPT $9.93
- Analyst Decision
- LEGH Strong Buy
- EYPT Strong Buy
- Analyst Count
- LEGH 2
- EYPT 8
- Target Price
- LEGH $29.00
- EYPT $24.75
- AVG Volume (30 Days)
- LEGH 100.7K
- EYPT 798.8K
- Earning Date
- LEGH 08-07-2025
- EYPT 08-06-2025
- Dividend Yield
- LEGH N/A
- EYPT N/A
- EPS Growth
- LEGH 8.04
- EYPT N/A
- EPS
- LEGH 2.29
- EYPT N/A
- Revenue
- LEGH $176,618,000.00
- EYPT $56,042,000.00
- Revenue This Year
- LEGH N/A
- EYPT N/A
- Revenue Next Year
- LEGH $8.23
- EYPT N/A
- P/E Ratio
- LEGH $10.04
- EYPT N/A
- Revenue Growth
- LEGH N/A
- EYPT 12.04
- 52 Week Low
- LEGH $21.58
- EYPT $3.91
- 52 Week High
- LEGH $29.31
- EYPT $13.99
- Technical
- Relative Strength Index (RSI)
- LEGH 53.84
- EYPT 59.24
- Support Level
- LEGH $23.25
- EYPT $9.45
- Resistance Level
- LEGH $24.20
- EYPT $11.69
- Average True Range (ATR)
- LEGH 0.65
- EYPT 0.77
- MACD
- LEGH 0.07
- EYPT -0.04
- Stochastic Oscillator
- LEGH 62.17
- EYPT 45.71
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.